Telesis Bio, Inc. (NASDAQ:TBIO) Short Interest Update

Telesis Bio, Inc. (NASDAQ:TBIO) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 51,400 shares, an increase of 19.3% from the June 30th total of 43,100 shares. Based on an average trading volume of 44,000 shares, the short-interest ratio is currently 1.2 days. Approximately 10.4% of the company’s stock are sold short.

Telesis Bio Stock Up 2.7 %

Shares of TBIO stock traded up $0.11 during mid-day trading on Monday, hitting $4.21. The company’s stock had a trading volume of 22,206 shares, compared to its average volume of 38,937. The company has a debt-to-equity ratio of 22.76, a quick ratio of 3.08 and a current ratio of 3.65. Telesis Bio has a 52-week low of $3.03 and a 52-week high of $28.80. The stock has a market cap of $7.09 million, a price-to-earnings ratio of -0.15 and a beta of 1.74. The business has a 50-day moving average price of $3.84 and a 200 day moving average price of $5.95.

Telesis Bio (NASDAQ:TBIO) last posted its earnings results on Thursday, May 9th. The company reported ($99.28) earnings per share (EPS) for the quarter. Telesis Bio had a negative net margin of 183.66% and a negative return on equity of 359.32%. The company had revenue of $3.44 million for the quarter, compared to the consensus estimate of $6.90 million.

Telesis Bio Company Profile

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.